Legal & General Group PLC X4 Pharmaceuticals, Inc Transaction History

Legal & General Group PLC

$470 Billion
Q3 2024

A detailed history of Legal & General Group PLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Legal & General Group PLC holds 18,609 shares of XFOR stock, worth $15,259. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,609

Previous 18,609 -0.0%

Holding current value

$15,259

Previous $12,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.58 - $1.47 $4,224 - $10,706	7,283 Added 64.3%	18,609 $10,000
Q3 2023 Nov 14, 2023	SELL	$1.03 - $2.02 $2,136 - $4,189	-2,074 Reduced 15.48%	11,326 $12,000
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $10,988 - $33,366	13,400 New	13,400 $25,000
Q2 2021 Aug 12, 2021	SELL	$6.49 - $9.56 $9,235 - $13,603	-1,423 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$6.09 - $9.15 $2,667 - $4,007	-438 Reduced 23.54%	1,423 $10,000
Q2 2020 Aug 14, 2020	SELL	$7.98 - $10.44 $4,077 - $5,334	-511 Reduced 21.54%	1,861 $17,000
Q1 2020 May 14, 2020	SELL	$6.03 - $11.01 $723 - $1,321	-120 Reduced 4.82%	2,372 $21,000
Q4 2019 Feb 13, 2020	BUY	$9.93 - $14.33 $5,074 - $7,322	511 Added 25.8%	2,492 $27,000
Q3 2019 Nov 13, 2019	BUY	$11.06 - $15.75 $9,024 - $12,852	816 Added 70.04%	1,981 $25,000
Q2 2019 Aug 14, 2019	BUY	$12.57 - $21.67 $12,984 - $22,385	1,033 Added 782.58%	1,165 $17,000
Q1 2019 May 15, 2019	BUY	$15.19 - $22.98 $2,005 - $3,033	132 New	132 $2,000

Others Institutions Holding XFOR

# of Institutions

103

Shares Held

99.9M

Call Options Held

213K

Put Options Held

50.6K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $56.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC X4 Pharmaceuticals, Inc Transaction History